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Abstract
Increasingly, single armed evidence is included in Health Technology Assessment submis-
sions when companies are seeking reimbursement for new drugs. While it is recognised that
Randomised Controlled Trials provide a higher standard of evidence, these are not available for
many new agents which have been granted licences in recent years. Therefore, it is important
to examine whether alternative strategies for assessing this evidence may be used.
In this work, we examine approaches to incorporating single armed evidence formally in
the evaluation process. We consider matching aggregate level covariates to comparator arms
or trials, and including this evidence in a Network Meta Analysis. We consider two methods
of matching; 1. we include the chosen matched arm in the dataset itself as a comparator for
the single arm trial, 2. we use the baseline odds of an event in a chosen matched trial, to use
as a plug-in estimator for the single arm trial.
We illustrate that the syntheses of evidence resulting from such a setup is sensitive to the
between study variability, formulation of the prior for the between design effect, weight given
to the single arm evidence, and the extent of the bias in single armed evidence. We provide
a flow chart for the process involved in such a synthesis, and highlight additional sensitivity
analyses that should be carried out. This work was motivated by a Hepatitis C dataset where
many agents have only been examined in single arm studies. We present the results of our
methods applied to this dataset.
1. Introduction
A Network Meta Analysis (NMA)1–8 allows researchers to formally combine all relevant direct
and indirect evidence in order to give the best possible evidence to decision-makers. Randomised
Controlled Trails (RCTs) are considered the gold standard of evidence, as their controlled approach
minimises potential bias. However, sometimes not all treatments have been evaluated in an RCT,
and the only available evidence on a treatment may be from sources such as observational studies
or single-arm studies. These types of evidence may contain valuable information, especially when
no other evidence is available, but they may potentially be biased (9–11). In a well conducted RCT
we can be confident that the patients are exchangeable across treatment arms, as they have been
randomly assigned. However, the same cannot be said for non-randomised evidence.
In one of the most recent reviews of its kind, Griffiths and Vadlamudi12 examined submissions
to three Health Technology Assessment (HTA) agencies between 2010 and 2015; NICE (UK),
CADTH (Canada), and IQWiG (Germany). The proportion of HTA submissions that considered
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non comparative evidence was 38%, 13%, and 12% for each agency respectively, although this may
be a broader sample than simply single arm trials. Submissions based exclusively on non compar-
ative evidence was 4%, 6%, and 4% respectively, making a total of 27 submissions, although some
of these submissions may have included Individual Patient Data (IPD). Positive outcome rates for
non comparative evidence alone versus overall submissions were 60% versus 84% for NICE, 69%
versus 68% for CADTH, and 17% versus 38% for IQWiG. From this analysis it is clear that when
RCTs are unavailable, HTA decision-makers are willing to consider non-comparative evidence,
despite its limitations. Given that single arm evidence is being accepted by HTA agencies, it is
essential to minimise potential bias by providing clear guidelines for incorporating this evidence
into an NMA. In 2016 Bell et al13 identified “priority research requirements” such as explorating
the consequences of data being drawn from different settings for invention and its compator, and
“the extent to which observational designs can complement or replace those of RCTs”.
Matching-Adjusted Indirect Comparisons (MAIC)14,15 or Simulated Treatment Comparisons
(STC)16,17 are emerging methods for reducing bias when incorporating single arm trials into an
NMA. However these require IPD for at least some of the studies, and it is frequently the case that
only aggregate data is available.
Much research has been undertaken on the inclusion of non-randomised evidence into an NMA
to date. Sutton et al18 investigate incorporating observational evidence in a pairwise meta analysis,
while Schmitz et al19 and Efthimiou et al20 propose methods for including observational studies
in an NMA in a manner that treats both evidence types separately. Thom et al21 and Goring et
al22 investigate methods of including single arm evidence. Thom et al propose using a random
effects model for the expected placebo effect in order to incorporate single arm evidence into an
NMA. However, this interferes with the randomisation of the RCT evidence. Goring et al estimate
absolute treatment effects and compare the results of their models to the recommended relative
effects models. Other work on absolute versus relative effects includes Hong et al23,24. However,
it has been argued by Dias et al25 that absolute effects “effectively breaks randomisation, and in
fact runs against the entire way in which randomised controlled trials are designed, analysed, and
used”.
Here we aim to address the research requirement proposed by Bell et al by assessing the appro-
priateness of including single arm evidence in an NMA through matching to other arms or trials
with similar patient covariates. As we are dealing with single arm studies we match on both effect
modifiers and prognostic variables, as recommended in Phillippo et al26,27. Firstly, we consider a
method of choosing another arm from the network. This means that we treat the single arm and the
chosen matched arm as if they are arms from the same study. We consider a naive pooled method
and a more formal hierarchical model. The first approach was recently adopted by Jaff et al28 in an
application to assess the efficacy of endovascular interventions. They compare the NMAs which
do and do not include single arm trials using matching. Schmitz et al29 also use a pooled model
to include single arm trials, and investigate the appropriateness of these models depending on how
close the matches are to the single arm trial. Secondly,we match to a chosen trial by plugging in
the baseline odds of an event in a chosen matched trial for the reference treatment. We compare
these different models and evaluate the performance in a simulation study. We also recommend a
number of sensitivity analyses which can be used to detect bias. This is illustrated in Section 4 by
using an example from the treatment of Hepatitis C Virus (HCV) infection.
There are a number of advantages to our methods over the methods described above:
1. The method only requires aggregate data.
2. Although including matched evidence adds non randomised evidence into the network, the
randomisation of the available RCTs is kept intact.
3. The methods fit within the relative effects framework.
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4. We can apply this method to a network of any size.
The objectives of this paper are to:
1. Assess which parameters influence the accuracy of the model’s estimate in an NMA;
2. Assess under what circumstances it is appropriate to include single arm evidence.
The remainder of this paper is organised as follows: A detailed description of the matched
arm methodology is provided in Section 2. Choices of hyperparameters are also comprehensively
discussed. Section 3 describes the construction and results of a comprehensive simulation study.
Section 4 presents our methods applied to a HCV infection network. A general discussion and
some recommendations are provided in Section 5.
2. Methods
2.1 Model Development
We construct a model where we observe rij , the number of events in the jth arm of the ith trial.
Treatment 1 is considered the overall reference treatment, with all other treatments being compared
to it. rij ∼ Bin(pij, nij), where pij is the probability of an event in the jth arm of the ith trial and
nij is the number of patients in the jth arm of the ith trial. nij is a fixed, observed quantity and pij
is made up of δij , the treatment effect in the jth arm of the ith trial and µi, the log odds of having
an event in the baseline treatment (i.e. in arm one) for study i. We assume a random effects model,
δij ∼ N(dtij − dti1 , σ2δ ), where dtij denotes the effect of the treatment in the jth arm of the ith trial
relative to the reference treatment and σδ represents the between trial standard deviation (SD) of
the treatment effect. tij is the treatment in the jth arm of the ith trial, which we can refer to as
treatment k. Let dk denote the effect of treatment k relative to the reference treatment for the NMA
as a whole. Note that dti1 will only equal zero if the first treatment in a given study is the reference
treatment for the NMA as a whole.




µi + δij if j>1
(1)
with priors µi ∼ N(0, 1.832), dk ∼ N(0, 1.832) and σδ ∼ Unif(0, 2) in the case of two arms. We
can adjust for trials with more than two arms by following Dias et al30. A table of the glossary of
notation used throughout this paper is included in the supplementary material.
The hyper-parameters for µ and d are chosen in order to have an approximate uniform distri-
bution on the log odds ratio. Kass and Wasserman31 point out that the properties of a prior on one
scale can differ when transformed to another scale. A seemingly vague prior such as N(0, 1002) is
not vague on the inverse logit scale, as most of the distribution is close to either 0 or 1. However,
the choice of σ = 1.83 means that two standard deviations on each side of the mean covers 95%
of the transformed (approximately uniform) distribution. This is illustrated in Leahy et al32. For
the prior for σδ, when transformed to the probability scale, two standard deviations cover the range
(0.02, 0.98), which we deemed to be sufficiently vague. This prior has also been examined by
Lambert et al33. We compare the log odds ratios (LORs) for the RCT only dataset using a stan-
dard WinBugs prior versus the prior proposed in this paper. A table of the results is shown in the
supplementary material.
2.2 Including Single Arms
We look at a number of ways for incorporating single arm trials into an NMA.
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1. (a) Including the matched arm in data - pooled model: We treat the single arm trial and its
chosen match as if they come from the same trial. In this case we group all evidence
types together in such a way that different forms of evidence are not distinguished by
the model. This is the most straight-forward model to implement and is set up as in
Equation 5. In this case the number of studies is the total number of RCT and matched
studies.
(b) Including matched arm in data - hierarchical model: Again, we treat the single arm trial
and its chosen match as if they come from the same trial. In this model we estimate
the treatment effect, d, at each level of the study design, and then combine to give the
overall treatment effect. This model provides more flexibility, at the cost of requiring
a more stable network structure. The schematic of this model can be found in the
supplementary material.
2. Plug-in estimator model: We assume the log odds of having an event on treatment 1 (refer-
ence treatment) is the same for the single arm trial and the chosen matched trial. This model
has the advantage of not using any data more than once. Both the RCTs and the single arm
trials are pooled as in model 1a above.
When using matching to incorporate single arm trials into an NMA, the main concern is that
the chosen comparator will include patients from a very different population to the single arm
trial. This could add bias to the model as one treatment could end up looking superior when it was
simply allocated to a particularly healthy patient population. In order to minimise this potential
bias we propose to choose matched comparators with the closest patient characteristics. When
including a matched arm in the data (Model 1a or 1b), this match can be any other arm in the
network, from either an RCT or another single arm trial, provided that the treatment is not the
same as the treatment in the single arm to which we are matching. Let M be the number of
covariates considered, let xmk be the proportion of patients possessing the characteristic associated
with the covariate in the single arm trial with treatment k, and let xmij be the proportion of patients
possessing the characteristic associated with the covariate in arm j of study i. The difference is:
∆ij,k =
∑M
m=1|xmij − xmk |. When matching to a trial using a plug-in estimator (Model 2) we can
choose to match to any RCT, regardless of which treatment it contains. In this case the difference
simplifies to: ∆i,k =
∑M
m=1|xmi − xmk |. In our example, since we look at binary covariates, x is a
proportion. However, this can easily extend to continuous covariates where x is the mean value of
the covariate. The full steps and sensitivity analyses that can be carried out when matching single
arms is presented in a flow diagram in Figure 1.
For the hierarchical model the extra level on the treatment effect is modeled as follows:
dRCT[k] ∼ N(d[k], σ2des)
dMATCHED[k] ∼ N(d[k], σ2des),
(2)
where σdes is the between study design SD which represents the variability between the RCT and
matched studies. This is essentially a random effects model for the study design level. The prior
distributions for d are the same as for the standard and pooled NMA models, and σdes ∼ unif(0, 2).
A benefit of the hierarchical model is that we can adjust for overprecision in the matched arms
by applying a multiplicative factor ω to the matched precision, thus inflating the variance. This
represents our increased uncertainty in the evidence from the matched arms, and can be thought
of as the weight given to the matched evidence. For example, if ω is small this indicates that we
believe that the matched evidence is a poor estimate of the mean effect.







Figure 1: Steps to be taken when carrying out the matching by including an extra arm in the data, and
recommended sensitivity analyses. xmij is the proportion possessing the characteristic associated with the
binary covariate m (or mean of in the case of a continuous covariate m) in the jth arm of the ith trial,
xmk is the proportion possessing the characteristic associated with the binary covariate m (or mean of
the covariate in the case of a continuous covariate m) in the comparison arm, K is the total number of
treatments examined in single-arm trials, and M is the total number of identified covariates.
Schmitz et al19 investigate a number of different models for incorporating different types of
evidence into an NMA and propose the hierarchical model as the best option, as we can obtain
estimates for each study design levels, and down-weight certain types of evidence. However, due
to the extra level in a hierarchical model, estimates may often be less certain and can be drawn
closer to zero.
The plug-in estimator model is written for the RCT part as:
logit(pij) = νi + δij (4)
and the matched part is written as:
logit(pl) = νChosenRCT[i] + δl (5)
where νi is the log odds of having an event for treatment 1 in trial i, and ChosenRCT[i] represents
the chosen trial to match to single arm trial l. For the matched part of the model the j subscript is





We compare the results of the matching methods (i.e. using the eight RCTs and the 4 matched
RCTs) to only using the evidence from the eight RCTs. We also include a scenario in which we
randomly choose a matched arm, in order to assess how much value there is in finding the best
match. The parameters that are varied in the simulation study are described in Table 1 and are
highlighted on the Directed Acyclic Graphs (DAGs) in Figure 2.
Table 1: Details of parameters varied in each scenario in the simulation study
Parameter Description Range Notes
σµ. The SD of the baseline study effect.
This is the measure of variability that
will be used throughout this paper. It
is the standard deviation of the logit
of the baseline risk of having an event
in each study in the network.
0-1.18 The highest value of 1.18 is approximately
3 times as large as the estimate of σµ in the
HCV infection network. It should be noted
that we chose to investigate this measure,
instead of the more commonly investigated
between-study heterogeneity, which quanti-
fies how relative treatment effects varying be-
tween trials. When matching single arm tri-
als we are interested in matching on prog-
nostic variables and effect modifiers, whereas
the between-study heterogeneity in RCTs is
only affected by effect modifiers. Since σµ
is driven by both unidentified prognostic vari-
ables and effect modifiers, we consequently
use this as our measure of between study vari-
ability.
ξ The bias in the single arm trials. The
mean of the logit of the baseline risk
of having an event in the RCTs comes
from a fixed distribution N(0, 0.592),
while the mean of the logit of the
baseline risk of having an event of the
single arm studies varies between 0
and 1. In the most extreme case the
single arm trials are simulated from
N(1, 0.592).
0-1 This corresponds to a baseline rate of 75% on
the probability scale, so we believe that this is
a sufficiently high value to use as the mean to
cover plausible scenarios.
z The upper bound of the uniform prior,
(0, z) on the between study design ef-
fect in the hierarchical model ,σdes.
0.25-2 We believe 2 is a sufficiently vague upper
bound as two standard deviations cover the
range (0.02, 0.98) on the probability scale.
ω The variance inflation on the matched
evidence in the hierarchical model
0.1-1 This has the effect of downweighting the
matched evidence.
When examining the hierarchical model, in order to examine the impact of model misspecifi-
cation, two further scenarios were considered:
• Extra RCTs: When examining the prior on the between study design effect, σdes, we also









(a) DAG for the simulation study. The
parameters that are varied are
dependent on the data themselves, and
the investigator has no input. Note: ξ












(b) DAG for Hierarchical Model. The parameters
varied are modeling choices which are chosen by
the investigator. Note: This DAG simplifies to the
RCT or Pooled Model by excluding all
hyper-parameters on dtij .
Figure 2: Directed Acyclic Graphs for simulations and models. The red box around certain nodes indicates
that these are varied in a simulation study. Square nodes represent fixed quantities while the ellipses are
stochastic nodes. The shaded nodes represent observed quantities.
hierarchical model, and four on the other side. This is to quantify the effect of the prior on
the hierarchical model versus the effects of genuine difference in study types.
• RCT By Omega: When examining the variance inflation of the matched evidence in the hi-
erarchical model, ω, we also include ω acting on the RCTs instead of the randomly matched




A network of 12 studies with seven treatments was simulated. The studies consisted of eight
two-armed RCTs and four single arm studies. The RCT studies consisted of treatments numbered
1-5 and the single arm studies consisted of treatments 1, 2, 6 and 7. To ensure our results were
applicable to a wide range of real world networks we kept our network as generic as possible, and
randomly assigned treatments to the RCTs at each iteration. Additionally, the treatment effects,
study effects and covariate effects were simulated at each iteration. Further details on the network
structure can be found in the supplementary material.
Data was simulated as follows:
1. We simulated:
• the study effect µi;
• the treatment effect dtij ;
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• the effect of one baseline binary covariate β;
• xijl, an indicator variable representing whether or not each patient has the covariate.
2. We computed the logit probability of an event for each individual patient l, in arm j of study
i: logit(pijl) = µi + dtij + βxij .
3. rijl was simulated from Bernoulli(pijl) for each patient l.
4. As we examining aggreagate data in this paper, we aggregated rijl to give an event rate for
each arm, rij . In the case of continuous covariates our summary would be the mean, which
takes the place of the proportion in the model. Thus our approach can be extended in a
natural fashion to continuous covariates.
3.1.2 Default Values
The default values were chosen based on the HCV infection network in Section 4 or based on
vague prior distributions. Each parameter was simulated independently. The values were set as
follows:
• The between study variability, µi ∼ N(0, 0.592). The default of 0.59 is half way through the
range on which we are varying the between study variability.
• The relative difference of treatments to baseline, dk ∼ N(0, 1.832), which is a broad range
for this parameter.
• The number of patients for single arm trials was simulated from ni ∼ Unif(75, 134), which
reflected the inter-quartile range of the size of trials in the HCV infection network. The
number of patients in the RCTs was twice this value.
• The probability of patients possessing each covariate was sampled from Unif(0, 1) for each
trial in order to cover the full range of possibilities. From this, each individual patient having
the covariate was sampled from a Bernoulli distribution with the trial probability of hav-
ing the covariate. This ensured that the RCT trials reflected the real world situation where
treatment arms are exchangeable.
• The covariate effect size, β = −1.04, was set to be twice as large as the largest estimated
covariate effect we found when analysising the RCT studies through a meta regression34
in our HCV infection example, and was therefore thought to be adequately large to reflect
possible real world covariates.
3.1.3 Implementation
We ran the models as described in Section 2 to assess how well they predicted the true relative
treatment effects, d. Models were run using Markov chain Monte Carlo (MCMC) simulation
in OpenBugs35. A burn in of 20 000 iterations was tested for convergence using the Gelman-
Rubin statistic36. Following this another 10 000 iterations were sampled for our estimates. If the
convergence condition was not met the number of iterations was doubled (both for the burn in and
for the samples for estimation) and then tested again until the Gelman-Rubin statistic was less than
1.1. If the chains had not converged after a burn in of 320 000 this iteration was excluded from
the analysis. Given the amount of simulations required we decided it was not feasible to include
chains that had not converged by this point. If the chains did not converge for one of the models
in a particular simulation the results for all other methods in the simulation were excluded from
the analysis in order to eliminate any potential bias due to differing simulations. We varied each
parameter in turn and sampled 8-12 data points for each at least 200 times.
In order to assess whether including single arm trials produces more accurate estimates than







/T , where d̂k is our model’s estimate of the relative effect of treatment
k, compared to treatment 1, and T is the number of simulations. A lower MAE means that the
model produces a more accurate estimate of the treatment effect.
We also compare the posterior SD as reported in the BUGS output to quantify the uncertainty
in the resulting estimates. While we might expect a lower posterior SD when more evidence is
added into the model, this might not necessarily hold due to the potential bias from the single arm
studies. Graphs showing the MAE and BUGS posterior SD are included in the results section.
3.2 Results
The graphs in this section show the lines of best fit for the simulated data points, obtained by
regression using both a linear and a quadratic term. Graphs showing the original data and the
Monte Carlo Error (MC Error) of the simulations are included in the supplementary material. For
simplicity, we use a pooled model for all analyses that do not directly investigate the nature of the
hierarchical model.
3.2.1 Parameters considered in exploratory analysis
In an exploratory analysis a number of parameters were examined through the simulation study.
We analysed the magnitude of the covariate and found that for larger covariate effects there was an
increased advantage of choosing a matched arm based on covariates over a randomly chosen match.
However, the magnitude of the covariate effect chosen for the simulation study was based on how
large we would reasonably expect a single standardised covariate to possibly be. Heterogeneity
between treatment effects was also examined. When there was large heterogeneity all methods
were less accurate and less precise at estimating the treatment effect. However the loss of accuracy
and precision was more pronounced for the RCT only evidence than when matched evidence was
included. Finally, we examined how trial size affected the accuracy of treatment effect estimation.
We found that including matched evidence was most beneficial when trials were small. For the
remainder of this Section we will focus on the parameters highlighed in Section 3.1.1.
3.2.2 Between Study Variability
We examine the effect of the between study variability, σµ, on the accuracy of the estimate of the
treatment effect and the posterior SD in Figure 3. The baseline odds for the reference treatment is
centered at zero. As σµ increases, the accuracy of the estimates obtained by including the single
arm evidence decreases to a point where including single arm evidence produces less accurate
estimates than the RCT only model. The estimates are more accurate when the baseline odds
are close together for each study, as the information is more accurate in the model. However,
as the difference increases noise is added into the model by assuming that treatment arms in the
matched studies are exchangeable, when in reality they come from different distributions. The
plug-in estimator model becomes worse than the pooled model when σµ is large. The MAE will,
of course, be larger for the treatments that are not in any RCTs. The error for treatments 6 and 7
alone when matching by covariate in the pooled model is between 0.57-1.52 as σµ varies from 0 to
1.18.
The crossing point is of particular interest as this is the decision point of whether to include
the matched evidence or not. As we see from Figure 3, the crossing point occurs at a higher
point for the posterior SD than for the MAE. This implies that at this point we may think that the
matched evidence is beneficial, when it is actually harmful. In Table 2 we estimate the between
study variability for the HCV infection network, as detailed in Section 4, and a number of publicly
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available datasets with binary outcomes from the statistical software package, R (37). The estimates
of σµ are of the order of, if not greater than the crossing point in the graph, indicating that matched
evidence may often lead to an increase in bias. It may be worth noting that the dataset with the
most objective outcome of mortality, i.e. the thrombolytic dataset has one of the lowest between
study variability.
Table 2: Between study variability in example networks
Dataset σ̂µ Source Outcome Description
Thrombolytic 0.36 gemtc in R Mortality after 30-35 days.
Hepatitis C 0.39 details in Section 4 SVR after 12 or 24 weeks.
Certolizumab 0.35 gemtc in R Improvement of at least 50% on the
American College of Rheumatology scale
(ACR50) at 6 Months.
Smoking 0.59 pcnetmeta in R Successful cessation of smoking at 6-12
months.
Depression 0.61 gemtc in R Reduction of at least 50% from the base-
line score on the HAM-D or MADRS at
week 8 (or, if not available, another time
between week 6 and 12).
Figure 3: Effect of between study variability, σµ, on the MAE and posterior standard deviation. Covariate
effect, β=-1.04. The extreme left point on the graph shows the scenario where the study effect is set to zero
for every study. The variability between the studies increases with the horizontal axis.
Figure 4 examines the danger of incorrectly assuming that the single arm studies come from
the same distribution as the RCTs. We see that the estimates and posterior SDs increase slightly as
the bias increases.
3.2.3 Hierarchical Model
We now look at the hierarchical model, which includes a between study design effect. We exclude
the plug-in estimator model from these results as this model would not be affected by the parame-
ters that are varied in this section. Figure 5 shows how varying the upper bound of the prior on the
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Figure 4: Effect of varying the bias in the single arm trials on the MAE and posterior standard deviation.
Between study variability, σµ=0.59, covariate effect, β=-1.04. The study effect in the RCTs comes from N(0,
0.59). The value on the x-axis indicates the mean of the single arm trials. Hence, at the extreme left point
both the single arms and RCTs come from the same distribution.
between study design effect affects the MAE and the posterior SD. The prior on the between study
design effect is given by Unif(0, z) where z varies along the x-axis. The RCT only model has the
same estimate at each point as there is only one study type in this model, therefore we have used
the average value over all simulations for this line.
As the upper bound of the prior on the between study design variance increases, the MAE and
posterior SD also increases. There is a fourth line on the graph corresponding to 12 RCT studies,
where we artificially group eight on one side of the hierarchical model, and four on the other side.
Here we see the same trend as before, with the posterior SD increasing as the prior on the between
study design σdes increases. However, this time it happens to a lesser extent. The increase in
posterior SD when including the extra RCTs is solely due to the prior. Any extra increase for the
matching methods is due to actual differences between the study types.
Figure 6 shows the effect that down-weighting matched evidence, ω, has on the accuracy of
our model’s estimate of the treatment effect and the posterior SD. Again, the RCT only line is the
average value over all simulations, as there is no weight on the matched evidence. The “RCT By
Omega” line shows ω acting on the RCT evidence instead of the (randomly) matched evidence.
Decreasing the weight of the high quality RCT evidence generally gives less accurate estimates
and larger posterior SDs. However, decreasing the weight of the matched evidence actually gives
a concave downwards shape. The MAE and the posterior SD is smallest when ω = 0.1, i.e.,
the smallest weighting in the simulation study. However, weighting the matched evidence fully
appears to be preferable to, or at least as good as, some of the values for ω in the centre of the
graph.
4. Example: Hepatitis C Virus - Treatment Naive Patients - NMA
As our research was motivated by a network of treatment regimens for the treatment of HCV
infection, we loosely based the simulation study on this network. Chronic HCV infection is a
global health burden of major concern. A number of treatment combinations are currently licensed
for genotype 1 (GT1) HCV infection. At the time of this systematic review there was a wealth of
clinical trial evidence available that compared single regimens in terms of treatment duration and
11
Figure 5: Effect of the prior on the between study design effect (σdes) on the MAE and posterior standard
deviation. Between study variability, σµ=0.59, covariate effect, β=-1.04. The horizontal axis shows the
upper bound for the prior on the between study design effect unif(0, z). Taking two standard deviations for
the largest value of an upper bound of 2 corresponds to (0.02, 0.98) on the probability scale.
Figure 6: Effect of ω on the MAE and posterior standard deviation. Between study variability, σµ=0.59,
covariate effect, β=-1.04, prior on between study design effect, σdes ∼ unif(0, 2).
with or without the addition of ribavirin. However, head-to-head comparative trials between all
licensed regimens for GT1 infection were unavailable.
There has been a major change in the way that newer HCV infection treatments have been
formulated22. There has been a move away from non-specific anti-viral therapies, which had rela-
tively low levels of cure rates, to antiviral combination therapies that directly target replication of
the virus, with the ability to significantly enhance cure rates. While RCTs are the most appropriate
method to directly assess the relative efficacy of all regimens from a methodological perspective,
RCTs comparing newer treatment regimens to older (and most probably inferior) treatments may
not be appropriate from an ethical perspective. Therefore, most of the evidence available on the
newer HCV infection treatment regimens is disconnected from the older network, and in fact comes
in the form of single arm evidence. We therefore apply the techniques discussed in Section 2 to
indirectly estimate the relative treatment effect of licensed regimens for the treatment of GT1, by
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Table 3: List of treatment regimens with abbreviations
Abbreviation Treatment Regimen
PR Pegylated-interferon and ribavirin
DCV/PR Daclatasvir (+ pegylated interferon and ribavirin)
BOC/PR Boceprevir (+ pegylated interferon and ribavirin)
SIM/PR Simeprevir (+ pegylated interferon and ribavirin)
TEL/PR Telaprevir (+ pegylated interferon and ribavirin)
SOF/PR Sofosbuvir (+ pegylated interferon and ribavirin)
PrOD±RBV Paritaprevir boosted with ritonavir, ombitasvir and dasabuvir
(with or without ribavirin)
SOF/LDV±RBV Sofosbuvir and ledipasvir (with or without ribavirin)
DCV/SOF±RBV Daclatasvir + Sofosbuvir (with or without ribavirin)
SIM/SOF±RBV Simeprevir and sofosbuvir (with or without ribavirin)
SOF/RBV Sofosbuvir (+ ribavirin)
including single arm trials, in treatment naive patients with chronic GT1 HCV infection.
4.1 Methods
A systematic review was conducted in accordance with the criteria of the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses group (PRISMA)38 on 6th May 2015, and repeated on
24th November 2015 and on 14th May 2016. These cut off dates are based on the needs of informing
the clinical programme in Ireland. We identified 13 RCTs that looked at two interventions39–51
and 18 single arm trials with no comparator. There were 11 different regimens in our network.
In total the single arm studies examined seven different treatment regimens. We chose one arm
with no comparator from each treatment regimen to use in this example52–58. Where possible we
chose single arms that had full information on the covariates of interest. The full list of regimens
is described in Table 3. The outcome of interest was a binary outcome, Sustained Virological
Response (SVR).
We first ran an analysis which investigated the 13 RCT studies. We then matched the single-
arms to an arm of another study to act as the comparator regimen. We then re-ran the meta-analysis
using these matched arms. We used the pooled model, four hierarchical models, and the plug-in
estimator model. The first hierarchical model gave equal weight to both study types, the other
three hierarchical model provided sensitivity analyses by down-weighting the matched estimate by
multiplying the matched precision by ω = 0.7, ω = 0.4 and ω = 0.1.
The studies were matched according to the proportion of patients that were cirrhotic, had geno-
type 1a, and had viral load >800,000 IU/ml at baseline. These covariates were chosen, because
according to clinical expert opinion, they were likely to influence SVR, and because these were
reported in the majority of trials. Each single arm study was compared to every individual arm
(including other single arm studies) and the differences in their baseline characteristics were de-
termined. As we had more than one covariate to use for matching we added the difference in the
three covariates together. The arm with the smallest difference in baseline characteristics was then
chosen as the matched arm. Not all arms had information on each of the three characteristics. The
best match was chosen from the pool of arms that had at least the same amount of information
as the single arm trial. A network diagram of the RCT only network and a network including
the single-comparator studies is shown in figure 7. Note that for the plug-in estimator model the
closest trial was chosen instead of the closest arm, and therefore a network diagram comparing
13
matched treatments is not applicable for this model.
(a) RCT only
(b) Including matched evidence when matching
to arms
Figure 7: Network Diagram. Black nodes denote treatments in RCT trials only, white nodes denote treat-
ments in single arm trials only, and gray nodes denote treatments in both single arm trials and RCT trials.
Black solid lines represent RCT connections and dashed lines represent matched connections. The treatment
requiring the match has the arrow pointing towards it. Although SOF/LDV±RBV and SOF/RBV are in an
RCT they are treated as only being in a single arm trial as the RCT cannot be included as it is not connected
to the rest of the network.
4.1.1 Random Matching Arms - Sensitivity Analysis
It is possible that the results of the analysis could change based on the choice of matched arms. As
there are millions of combinations of arms, it is not possible to test all of them. Therefore, we ran
over 1 000 simulations to check matching arms at random in order to assess the sensitivity to the
choice of match.
4.1.2 Removing RCT arms
In order to assess the accuracy of matching on the Hepatitis C network we investigated how well
our method would work on RCTs, which we turned into single arm trials by removing arms. We
found an estimate of the efficacy of each drug by using only the RCT evidence. We excluded those
that did not have full information for the three covariates and were therefore left with nine RCTs
and four treatments: PR, TEL/PR, BOC/PR and SIM/PR. We then selected studies at random and
removed all the arms except one. We then matched these new “one-arm” studies to the remaining
studies in the network. We compared our results to the results of the reduced dataset with the
“one-armed” trials excluded to see which was closer to the estimate with nine trials. We compared
these results making a varying amount of studies into single arm trials, from one to six. In all cases
we ensured that there was at least one study with each treatment remaining in an RCT so that we
were comparing like with like.
4.2 Results
Table 4 shows the mean and posterior SD of the log odds ratios (LOR) for each treatment regimen
versus PR (standard of care). For treatment regimens which have both RCT and matched evidence
(TEL/PR, SOF/PR, and PrOD±RBV) including the matched evidence decreases the posterior SD
of the LOR in all cases. The hierarchical model generally results in higher posterior SDs than
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Table 4: Log Odds Ratio versus PR
Matched Hier Matched Hier Matched Hier
RCT Pooled Hierarchical Down-weighted Down-weighted Down-weighted Mu From
ω = 0.7 ω = 0.4 ω = 0.1 Matched
Regimen Mean Posterior Mean Posterior Mean Posterior Mean Posterior Mean Posterior Mean Posterior Mean PosteriorSD SD SD SD SD SD SD
DCV/PR 2.150 0.898 2.095 0.889 2.181 0.909 2.210 0.934 2.231 0.896 2.211 0.867 2.092 0.891
BOC/PR 1.104 0.232 1.102 0.256 1.107 0.228 1.107 0.218 1.110 0.225 1.111 0.227 1.106 0.224
SIM/PR 1.166 0.222 1.149 0.241 1.157 0.219 1.155 0.211 1.166 0.224 1.162 0.214 1.159 0.217
TEL/PR 1.064 0.208 1.123 0.202 0.928 0.571 0.973 0.549 0.938 0.585 1.025 0.433 1.115 0.176
SOF/PR 1.639 0.648 1.828 0.395 1.496 0.744 1.556 0.734 1.499 0.759 1.625 0.672 2.421 0.326
PrOD±RBV 3.243 0.613 3.560 0.437 3.115 0.794 3.152 0.784 3.087 0.794 3.249 0.693 3.827 0.438
SOF/LDV±RBV 3.944 0.601 3.081 1.161 3.247 1.161 3.172 1.188 3.295 1.116 4.149 0.645
DCV/SOF±RBV 1.898 0.945 1.520 1.320 1.615 1.362 1.587 1.393 1.775 1.417 2.927 1.023
SIM/SOF±RBV 2.757 0.658 2.121 1.215 2.201 1.236 2.163 1.220 2.357 1.231 2.999 0.623
SOF/RBV 0.861 0.685 0.623 1.160 0.708 1.207 0.591 1.172 0.807 1.227 1.120 0.539
the pooled model. This may be explained by the additional prior variance on the study effect.
However, for all treatment regimens with RCT evidence only (DCV/PR, BOC/PR and SIM/PR)
the adjusted hierarchical model with matched evidence down-weighted has the smallest posterior
SD. The pooled model generally gives a more extreme LOR than the hierarchical model, since in
the latter case the summary effect is shrunken toward zero. SUrface under the Cumulative RAnking
curve (SUCRA) scores59 are shown in the supplementary material.
4.2.1 Random Matching Arms - Sensitivity Analysis
Figure 8 shows the distribution of the LOR for each of treatment regimen versus PR. This can
identify how sensitive treatments are to the choice of match. We see that the treatment regi-
mens for which RCTs are available are quite small. However, the treatments regimens for which
only matched evidence is available are much larger. We can see that on average newer treat-
ments have the highest LOR (PrOD±RBV, which has both evidence types and SOF/LDV±RBV,
DCV/SOF±RBV, and SIM/SOF±RBV which all have single arm evidence only). This highlights
the importance of including these treatments in an NMA as they are likely to be better than the
older treatment regimens, which are included in RCTs. It is important to note here that most es-
timates from the chosen match give a smaller LOR than average. In particular we compare the
best match hierarchical model (denoted by a red triangle) with the distribution shown, as these
are the same models. This reassuringly highlights that we are at least being conservative with our
estimates of the single arm treatments.
4.2.2 Removing RCT arms
As we can see in Figure 9, in the hepatitis C network if we change three or fewer RCTs to single
arm trials the reduced model is slightly closer to the full network than using our matched methods,
on average. However, if we change five or six RCTs into single arm trials then all methods gives
results that are much closer to the full network than the results we obtain from the reduced dataset.
We also see that the estimate of the reduced dataset is less precise than the pooled model, and
thus the reduced model has the same or higher posterior SD than the plug-in estimator model. A
“U-shaped” curved is noticeable for the hierarchical model for the posterior SD. The reason for the
high uncertainty when we only match one or two studies is because we have very little evidence
on the matched side of the hierarchical model. From this analysis the pooled model would be the
most preferable.
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Figure 8: Distribution of the log odds ratio using randomly matching arms compared with results from RCT
only and the best match chosen by the equal weights method.
Figure 9: We use only one arm from a number of RCTs (as indicated on the x-axis). Results from the
reduced RCT network or network obtained by matching the new “single arm” studies are compared to our
best estimate of the treatment effect, i.e. the full nine study network.
5. Discussion
5.1 Summary
If there was sufficient RCT evidence there would be no need to include single arm evidence as it is
of lesser quality. However, sometimes only single arm evidence is available. Single arm evidence is
currently being used in HTA, so it is important that we find the most suitable method for including
such single arm evidence in an NMA, and that we understand the benefits and limitations of this
type of evidence. Figure 10 shows a schematic representation of the association between some of
the parameters considered in this paper and the MAE and posterior SD.
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Figure 10: Schematic representation of the association between the parameters and the mean absolute error
and posterior SD based on the results from the simulation study. Note that location and size of effects may
depend on other parameters as described in the text.
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also affect the appropriateness of including matched evidence. For these we tried to choose the
parameters in the simulation study so that they were as realistic as possible, and if anything they
favoured RCT evidence. In the exploratory analysis we found that matching was most valuable
when trials were small. Similarly, in the Hepatitis C example the matching method only showed
superiority over the reduced method once four or five studies had been removed.
There is a concern that allowing the inclusion of single arm evidence would disincentivise
further RCT research from being undertaken. There is also the question of whether we are willing
to accept a particularly biased estimate over no estimate at all. Therefore it makes sense to have
the option to down-weight the single arm evidence, so that it does not have the same impact as
RCT evidence.
5.2 Recommendations
We recommend considering single-arm evidence when the variability between studies is small and
when we can find an appropriate match. We can attempt to quantify this variability by examin-
ing the baseline effect across the RCTs. As the discrepancies between the studies increase, the
incorrect assumption of exchangeablity between matched arms leads to a decreased accuracy and
precision in the estimates. This form of evidence has a high possibility of being biased and should
be used with caution.
When undertaking single-arm matching there are a number of sensitivity analyses that should
be carried out:
1. Quantify the variability between RCTs;
2. Compare the results using the best match to the results using random matches;
3. Adjust the weight of the matched evidence in the hierarchical model by increasing the vari-
ance inflation.
It is important to emphasise that any method for incorporating single arm evidence cannot
replace the unbiased approach of an RCT. Given the large potential financial gain for a pharma-
ceutical company arising from a positive HTA recommendation, there is a clear incentive to ensure
that treatments look as effective as possible. Single arm trials are much more exposed to bias or
manipulation than RCTs60. Therefore, it is imperative that we bear this in mind when making deci-
sions based on single arm evidence. While aggregate level matching may be helpful in estimating
treatment rankings when no other evidence is available, we would not consider this type of evi-
dence to be convincing enough to be the primary source of evidence when making reimbursement
decisions. Although there are advantages in using single-arm evidence, the burden of proof must
be on the pharmaceutical company to demonstrate the benefits of their treatments using methods
that are as free from bias as possible.
5.3 Limitations and Extensions
In our simulations we made many assumptions about the size, shape and structure of the network.
The prior in the hierarchical model may be too vague for sparse networks, especially considering
that it may be quite difficult to estimate σdes given that we have only two study types. Therefore, it
may be worth considering an informative prior distribution formed by expert opinion as suggested
by Efthimiou et al20. Although our worked example only uses binary covariates, this method can
easily be applied to continuous covariates by using the mean in each trial.
In this paper we choose the closest match for each treatment regimen. However, there may be
other studies or arms that are nearly as similar as the chosen match. On the other hand, there may
be some treatments regimens for which all potential matches are very dissimilar to the single arm
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trial. In this case we may want to consider excluding this treatment regimen from the analysis.
Criteria for assessing a sufficiently similar match is discussed in Schmitz et al29.
It would also be worth checking if the best match is usually more conservative than a random
match in various networks. If so, it may indicate that single arm trials are more likely to give better
results (perhaps because of healthier patient recruitment) than RCTs and reinforce the point that
single arm evidence should be used with caution and covariates should be matched as much as
possible.
5.4 Conclusion
There is increasing motivation to use single arm evidence where available, as pharmaceutical com-
panies increasingly use this type of evidence to obtain regulatory approval. Methods such as those
explored in this paper are already being implemented in clinical practice, as seen in Jaff et al28.
There is a high risk of bias and considerable uncertainty arising from incorporating single arm evi-
dence into an NMA. Therefore it is imperative that the methods used are transparent, backed up by
systematic investigation, and a clear indication for how much bias could potentially be introduced
is provided.
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